BioCentury
ARTICLE | Distillery Therapeutics

Therapeutics: FMS-like tyrosine kinase 3 ligand (FLT3LG); BRAF; programmed cell death 1 ligand 1 (PD-L1; B7-H1; CD274)

May 19, 2016 7:00 AM UTC

Mouse studies suggest FLT3LG plus poly I:C could help treat BRAF-mutant melanoma. In a mouse model of BRAF-mutant melanoma, systemic injection of FLT3LG plus intratumoral injection of poly I:C decreas...